Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of N9-GP for prophylaxis and treatment of bleeding in haemophilia B
NL-OMON36266Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, single-blind trial of nonacog beta pegol in hemophilia B (HB) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Incidence of inhibitory antibodies against factor IX. Started Oct 2011; status: active, not recruiting.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON36266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36266.